The current use of ultrasound to measure skeletal muscle and its ability to predict clinical outcomes: a systematic review

Patrick Casey1,2*, Mohamed Alasmar1,3, John McLaughlin2,4, Yeng Ang2,4, Jamie McPhee6,7, Priam Heire5 & Javed Sultan1,3

1Department of Oesophagogastric Surgery, Salford Royal NHS Foundation Trust, Salford, UK; 2Division of Diabetes, Endocrinology and Gastroenterology, Manchester Academic Health Sciences Centre, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; 3Division of Cancer Sciences, School of Medical Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, UK; 4Department of Gastroenterology, Salford Royal NHS Foundation Trust, Salford, UK; 5Department of Sport and Exercise Sciences, Musculoskeletal Science and Sports Medicine Research Centre, Faculty of Science and Engineering, Manchester Metropolitan University, Manchester, UK; 6Manchester Metropolitan University Institute of Sport, Manchester, UK; 7Department of Musculoskeletal Radiology, Salford Royal NHS Foundation Trust, Salford, UK

Abstract

Quantification and monitoring of lean body mass is an important component of nutrition assessment to determine nutrition status and muscle loss. The negative impact of reduced muscle mass and muscle function is increasingly evident across acute and chronic disease states but is particularly pronounced in patients with cancer. Ultrasound is emerging as a promising tool to directly measure skeletal muscle mass and quality. Unlike other ionizing imaging techniques, ultrasound can be used repeatedly at the bedside and may compliment nutritional risk assessment. This review aims to describe the current use of skeletal muscle ultrasound (SMUS) to measure muscle mass and quality in patients with acute and chronic clinical conditions and its ability to predict functional capacity, severity of malnutrition, hospital admission, and survival. Databases were searched from their inception to August 2021 for full-text articles in English. Relevant articles were included if SMUS was investigated in acute or chronic clinical contexts and correlated with a defined clinical outcome measure. Data were synthesized for narrative review due to heterogeneity between studies. This review analysed 37 studies (3100 patients), which met the inclusion criteria. Most studies (n = 22) were conducted in critical care. The clinical outcomes investigated included functional status at discharge (intensive care unit-acquired weakness), nutritional status, and length of stay. SMUS was also utilized in chronic conditions such as chronic obstructive pulmonary disease, chronic heart failure, and chronic renal failure to predict hospital readmission and disease severity. Only two studies investigated the use of SMUS in patients with cancer. Of the 37 studies, 28 (76%) found that SMUS (cross-sectional area, muscle thickness, and echointensity) showed significant associations with functional capacity, length of stay, readmission, and survival. There was significant heterogeneity in terms of ultrasound technique and outcome measurement across the included studies. This review highlights that SMUS continues to gain momentum as a potential tool for skeletal muscle assessment and predicting clinically important outcomes. Further work is required to standardize the technique in nutritionally vulnerable patients, such as those with cancer, before SMUS can be widely adopted as a bedside prognostic tool.

Keywords: Skeletal muscle; Ultrasound; Muscle wasting; Sarcopenia; Malnutrition; Risk prediction
Background

Assessment of body composition goes beyond measuring overall body weight and is an important component of nutritional assessment in patients with both acute and chronic illness. European and American Societies for Parenteral and Enteral Nutrition guidelines (ESPEN, ASPEN) recommend the routine assessment of body composition with specific emphasis on lean mass.1,2 Skeletal muscle is the major component of lean body mass and plays an important homeostatic, metabolic, and physical functioning role. There is now a wealth of data to show that patients with reduced muscle mass and function (sarcopenia), and those who suffer acute muscle wasting during treatment, are at higher risk of treatment-related complications, take longer to recover, and have worse overall survival.3–7 This phenomenon transcends disease types but is especially pronounced in patients who are nutritionally vulnerable such as older patients and those with cancer.8 Low muscle mass combined with obesity is a particularly dangerous combination where significant loss of muscle may go undetected by simply monitoring body weight or anthropometrics alone.9 An appropriate bedside test is therefore required to quantify both muscle mass and quality so longitudinal changes in muscle can be monitored to help inform decisions about treatment and nutritional support. Whilst several tools exist for this purpose, each have their own technical pitfalls and practical limitations. Computer tomography (CT) and magnetic resonance imaging (MRI) are excellent at quantifying muscle mass and, more recently, muscle quality (myosteatosis).5 Whilst cross-sectional imaging can be retrospectively analysed, requiring these investigations for the sole intention of body composition analysis is not appropriate due to practical constraints, expense, and (in the case of CT) ionizing radiation. The ideal test should be inexpensive, non-ionizing, accurate, and sensitive enough to detect even small changes in muscle mass or quality. Ultrasound is emerging as a promising bedside tool for this purpose. Originally used to describe changes in adipose tissue (subcutaneous and visceral fat thickness),10 the focus has moved to the assessment skeletal muscle. The European Working Group on Sarcopenia identify ultrasound as a potentially useful method for evaluating skeletal muscle whilst accepting that further research is required.11 Muscle thickness, cross-sectional area (CSA), echointensity, pennation angle, and fascicle length are the key variables that offer both quantitative and qualitative analyses of muscle tissue. The validity and reliability of ultrasound to measure skeletal muscle has been the subject of recent systematic review and shown to have good interclass correlation coefficient and validity when compared with other imaging modalities.12–14 When standardized for age and sex, a four-site protocol (bilateral quadriceps and biceps) demonstrates excellent agreement with reference standards such as dual x-ray absorptiometry (DEXA) ($R^2 = 0.91$).15 Initial concerns regarding the lack of a standardized ultrasound technique are beginning to be answered as evidence from the geriatric and critical care setting expands.16–18 Furthermore, recent consensus guidelines on the optimal technique for each muscle site have been published and offer well-evidenced practical advice to further improve the reproducibility and validity of skeletal muscle ultrasound (SMUS).19 With this foundation, attention is now turning to the power of muscle ultrasound to inform and predict clinical and health-related outcomes. Before SMUS can become a reliable and integrated nutritional assessment tool, its ability to predict patient-centred outcomes requires investigation. The aim of this systematic review is to describe the current use of SMUS measurements (CSA, muscle thickness, and echogenicity) and its ability to predict clinically relevant outcome measures, such as functional capacity, length of stay, readmission, and survival in acute and chronic clinical contexts.

Search methods

PubMed, Cochrane Library, Embase, Ovid, Scopus, and Google Scholar were systematically searched for full-text articles in English from inception up until 1 August 2021. Outcomes of interest included the use of SMUS of any anatomical location (other than the diaphragm), which were associated with a clinical or functionally relevant outcome. The search included a combination of terms related to muscle mass, nutritional assessment, ultrasound, and clinical outcomes. Included was a combination of terms related to muscle mass, nutritional assessment, ultrasound, and clinical outcomes were used: (i) sarcopenia: muscular atroph*, muscle atroph*, muscle mass*, muscle size*, muscle diameter*, muscle volume*, muscle thickness*, muscle wasting; (ii) ultrasonography: ultrasound, ultraso* imaging, sonography; and (iii) nutrition*, nutrition screening, malnutrition. In addition, published reference lists were hand-searched and screened for additional resources.

Study eligibility and appraisal criteria

A broad range of disease types and clinical contexts were considered with the exception of papers assessing systemic neuromuscular pathology (e.g. hemiplegic stroke and neuromuscular degeneration) or primary muscular pathology (e.g. myositis), which were excluded. Studies were only included if reference to a specific and defined clinical or functional outcome was made as part of their primary analysis. These included acute admission metrics (complications, length of stay, length of ventilation, readmission, and in-hospital mortality), any validated assessment of functional, nutritional, and quality of life status, or survival. Studies that compared
or validated ultrasound metrics to other modalities (e.g. bio-electrical impedance analysis, CT, and MRI) or studies that only addressed technical aspects of ultrasound technique were excluded as this has been subject of recent systematic review. Studies in children (<18 years old) were also excluded.

Search results were exported, and duplicates deleted using Mendeley Desktop (2020, Version 1.19.8). After title and abstract screening, full-text articles were assessed for eligibility and quality and independently reviewed by two assessors (P. C. and M. A.). Disagreements were resolved by review and consensus by the senior lead author (J. S.). Studies were independently scored to assess methodological quality and relevance according to COSMIN guidelines plus a modified 10-point checklist modified from Pretorius and Keating who validated real-time ultrasound measurements of skeletal muscle. The consensus-based standards for the selection of health status measurement instruments (COSMIN) checklist consists of nine boxes containing multiple criteria, which are used to assess methodological quality. A score was determined by taking the lowest rating of each criterion and defined to be poor, fair, good, or excellent. Methodological quality was scored independently between reviewers, and agreement assessed using Cohen’s kappa coefficient where a score of >0.75 suggested excellent agreement, 0.75–0.4 as fair to good, and <0.4 as poor agreement between reviewers. Data were extracted from full manuscripts and imported for analysis. Data points collected included the clinical context of the study, technical aspects of the ultrasound equipment, scan technique adopted, the clinically relevant outcome investigated, and the statistical analysis used to assess correlations. Observational and cohort studies were classified as ‘positive’ if a statistically significant correlation (i.e. $P$ value < 0.05) was reported using appropriate statistical methodology. Negative studies were those that found no statistically significant association. Those lacking statistical or methodological detail (i.e. poor on COSMIN scoring and <6 on the modified quality checklist) were excluded from the review analysis. Randomized control trials were assessed using the same criteria; that is, ultrasound measures correlation with a defined clinical outcome even if this was measured as a secondary outcome. Preliminary assessment of the combined data demonstrated significant heterogeneity in terms of clinical context and outcome measures; therefore, no meta-analysis was performed.

**Results**

A summary of the study search process is outlined in the Preferred Reporting Items for Systematic Review and Meta-Analysis (PRISMA) flow diagram (Figure 1). After screening by title and abstract, 53 studies were assessed in detail for eligibility. A total of 37 studies (involving 3100 participants) were deemed eligible based on quality and relevance. The inter-rater agreement regarding study eligibility was rated excellent [Cohen’s kappa = 0.79 (95% confidence interval = 0.67 to 0.92)], and the agreement on the above defined methodological quality of each study was rated good [Cohen’s kappa = 0.61 (95% confidence interval = 0.51 to 0.71)]. The number of publications over the last 18 months ($n = 18$ studies) was similar to that of the preceding 11 years ($n = 19$ studies) highlighting the recent surge of new evidence (Figure 2). Data from 26 prospective observational studies (of which 6 were cohort studies, 7 cross-sectional...
studies, \(^{27,50-55}\) 3 randomized control trials, \(^{56-58}\) and 1 post hoc analysis of a negative trial were included. \(^{59}\) Five of the 37 studies involved an interventional arm [critical care nutritional intervention \((n = 4)^{44,56-58}\) and an exercise intervention in breast cancer \((n = 1)^{45}\)].

**Clinical context**

Most studies (59\%) were conducted in the critical care unit and described the impact of ultrasound-derived muscle loss in a general critical care population as part of their study. Ten studies (27\%) investigated patients with chronic disease in the outpatient setting [chronic obstructive pulmonary disease (COPD) \(n = 4\)^{26,34,52,55}\) heart failure \(n = 2\)^{51,53}\) chronic renal failure \(n = 2\)^{27,54}\) geriatric rehabilitation \(n = 1\)^{23}\) and liver cirrhosis \(n = 1\)^{31}\) whereas three studies were conducted during an acute admission (acute surgical, \(^{40}\) exacerbation of COPD, \(^{59}\) and acute geriatric admission\(^{46}\)). Only two studies were conducted in patients receiving treatment for cancer. \(^{45,50}\) Of the 37 studies, 15 reported the specialty and expertise of the individual performing the scans, dieticians \((n = 6)\) and medical staff \((n = 6)\) being the most frequently reported ultrasound technicians.

**Correlation with outcomes**

Overall, 28 of the 37 studies (76\%) were classified as a positive study having reported a statistically significant association between SMUS and a defined clinical or functional outcome. Two of the remaining nine negative studies reported strong trends on univariate analysis, which were then lost on multivariate analysis. \(^{40,46}\) The remaining seven negative studies found no association or correlation with any of the outcomes investigated. The mean number of patients recruited in the negative studies was 56 (±29), compared 91 (±63) in the positive studies \((P = 0.049)\). *Table 1* summarizes

---

**Figure 2** Preferred Reporting Items for Systematic Reviews and Meta-Analyses flowchart showing selection procedure.
| First author     | Year  | Clinical context                  | n   | Muscles group | Technique described            | US metric       |
|------------------|-------|----------------------------------|-----|---------------|--------------------------------|-----------------|
| Akazawa         | 2021  | Subacute - geriatric rehab       | 404 | RF, VI        | 1/3 thigh, no pressure         | MT, EI          |
| Bury             | 2020  | ITU - surgical                   | 52  | RF, VI        | 1/3 and 1/2 thigh, max pressure| MT              |
| Chappell         | 2016  | ITU - head injury                | 37  | RF, VI        | 1/3 and 1/2 thigh, max pressure| MT              |
| Cruz-Montecinos  | 2018  | Chronic - COPD rehab             | 20  | RF, VI        | 1/3 thigh, no pressure         | MT, EI          |
| de Souza         | 2018  | Chronic - CKD pre-dialysis       | 100 | RF            | Mid-thigh, no pressure         | CSA             |
| Dimopoulos       | 2020  | ITU - cardiac surgery            | 165 | RF, VI        | Mid-thigh, no pressure         | MT              |
| Escriche-Escuder | 2021  | Cancer - breast cancer           | 13  | RF, VI, BB    | Yes - but different to most other studies | MT, EI, CSA    |
| Ferrie           | 2015  | ITU - general                    | 119 | RF, VI, BB, forearm | 1/3 and 1/2 thigh, no pressure | MT, CS A       |
| Fetterplace      | 2018  | ITU - general                    | 60  | RF, VI        | 1/3 and 1/2 thigh, no pressure | MT              |
| Galindo Martin   | 2017  | ITU - general                    | 59  | RF, VI        | Mid-thigh, max pressure        | MT              |
| Gomes            | 2020  | Cancer complications/treatment   | 41  | RF, VI        | Inadequate detail              | MT              |
| Greening         | 2015  | Acute - COPD                     | 191 | RF            | Mid-thigh, no pressure         | CSA             |
| Gruther          | 2008  | ITU - general                    | 118 | RF, VI        | 1/3 thigh, no pressure         | MT              |
| Guerreiro        | 2017  | Acute - geriatric                | 100 | RF, VI        | Mid-thigh, no pressure         | MT, total Th, contract index |
| Hari             | 2019  | Chronic - cirrhosis              | 54  | Psoas         | Internal SOP                   | MT, CA          |
| Hayes            | 2018  | ITU - ECMO                       | 25  | RF, VI, VL    | 1/3 thigh, no pressure         | MT, EI, CSA    |
| Lee              | 2020  | ITU - general                    | 41  | RF, TA        | 1/3 thigh, no pressure         | MT, CA, EI, PA, FL |
| Mayer            | 2020  | ITU - general                    | 118 | RF, VI        | 1/3 thigh, no pressure         | MT, CA, EI, Pa  |
| Maynard-Paquette | 2020  | Chronic - COPD                   | 40  | RF            | 3/5 thigh, no pressure         | MT, CA, Q contractile index |
| McNelly          | 2020  | ITU - general                    | 121 | RF            | 3/5 thigh, no pressure         | MT, CSA        |
| Mueller          | 2016  | ITU - surgical                   | 102 | RF            | 60% point, no pressure         | MT, CSA        |
| Nakano           | 2020  | Chronic - HF                     | 58  | RF, VI, VM, VL| Mid-thigh, no pressure         | MT, EI          |
| Nijhoť           | 2019  | Chronic - COPD rehab             | 30  | RF            | Mid-thigh, no pressure         | MT, CSA        |
| Palakshappa      | 2018  | ITU - sepsis                     | 18  | RF, VI        | 1/3 thigh, no pressure         | MT, CSA        |
| Parr             | 2015  | ITU - general                    | 22  | RF, VI, VM, VL| 1/3 thigh, no pressure         | MT, CA, EI, PA  |
| Ria              | 2020  | ITU - liver failure              | 50  | RF            | 3/4 mark, no pressure          | MT, CSA, normalized to body SA |
| Puthucheary      | 2017  | ITU - general                    | 54  | RF            | Mid-thigh, no pressure         | MT, CA, EI     |
| Rodrigues        | 2020  | ITU - general                    | 60  | RF, VI        | 1/2 and 1/3 thigh, no pressure | MT, CA, EI     |
| Sabatino         | 2020  | ITU - renal                      | 30  | RF, VI        | Mid-thigh, max pressure        | MT              |
| Salim            | 2020  | Acute - surgical                 | 49  | RF, VI        | Mid-thigh, max pressure        | MT (normalized for limb length) |
| Sato             | 2020  | Chronic - HF                     | 185 | RF            | Mid-thigh, no pressure         | MT              |
| Sahatheven       | 2020  | Chronic - CKD on dialysis        | 351 | RF            | 1/3 thigh, no pressure         | CSA             |
| Tanaka           | 2020  | ITU - sepsis                     | 8   | RF            | Mid-thigh, no pressure         | MT              |
| Toledo           | 2021  | ITU - general                    | 74  | RF            | 1/3 and 1/2 thigh, no pressure | MT              |
| Witteveen        | 2017  | ITU - general                    | 71  | RF, TA, BB, FCR| Yes - defined landmarks for each muscle group | MT, EI          |
| Ye               | 2017  | Chronic - COPD                   | 50  | RF, VI        | Mid-thigh, no pressure         | MT, CA, EI     |

6MWT, 6 min walk test; ADL, activities of daily living; ASPEN, American Society of Parental and Enteral Nutrition; BB, biceps brachii; CFS, clinical frailty score; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CPET, cardiopulmonary exercise testing; CSA, cross-sectional area; D/C, discharge; ECMO, extra-corporeal membrane oxygenation; EI, echointensity; FCR, flexor carpi radialis; FEV1, forced expiratory volume 1; FFM, fat free mass; FL, fascicle length; GOLD, Global Initiative for Chronic Obstructive Lung Disease; GOS-E, Global Outcome Scale - Extended; HGS, hand grip strength; ICU, intensive care unit; ISRN, International Society of Renal Nutrition and Metabolism; ISWT, intermittent shuttle walk test; ITU, intensive treatment unit; ITU-AW, intensive treatment unit-acquired weakness; LBM, lean body mass; LOCCS, length of critical care stay; LOMV, length of mechanical ventilation; LOS, length of stay; MRC, medical research council strength score; MT, muscle thickness; MVCQ, mean voluntary contraction index; NUTRIC, nutritional risk in critically ill; PA, pennation angle; PEW, protein energy wasting; PG-SGA, Patient-Generated Subjective Global Assessment; PMI, psoas muscle index; Pear, psoas to height ratio; QLQ-BR, Quality of Life Questionnaire - Breast Cancer; QoL, quality of life; RF, rectus femoris; SA, surface area; SARC-F, strength, assistance, rising, climbing, and falls score; SF-36, short form-36; SOFA, Sequential Organ Failure Assessment; SOP, standard operating procedure; StS, sit to stand; TA, tibialis anterior; US, ultrasound; VI, vastus intermedius.
| First author        | Serial measurements | Clinical outcome investigated | Intervention | Main conclusion                                                                 | Positive or negative study |
|---------------------|---------------------|------------------------------|--------------|----------------------------------------------------------------------------------|-----------------------------|
| Akazawa23           | N                   | Barthel Index (ADL)          | N            | Poor echointensity on US correlates with delayed recovery of ADL                  | Positive study              |
| Bloch24             | Y - D0 and D7       | LOS, mortality, circulating biomarkers | N            | No correlation with clinical outcomes. Phenotypes of wasters vs. non-wasters identified | Negative study              |
| Bury44              | Y - D0-10           | ASPEN nutrition grade, LOS, vent days | Y - nutrition supplement | US can detect muscle loss and correlates with degree of malnutrition             | Positive study              |
| Chapple25           | Y - weekly and 3/12 post-discharge | Physical function (SF-36), GOS-E | N            | US detects muscle loss and correlates with physical functioning role and LBM      | Positive study              |
| Cruz-Montecinos26   | N                   | 6MWT, MVCQ                   | N            | US correlates with exercise capacity and strength                                 | Positive study              |
| de Souza27          | Y - D1, 3, 5, 7     | MRC score, LOCCS, LOMV       | N            | Baseline low MT is associated with prolonged ITU stay                            | Positive study              |
| Escriche-Escuder45  | Y - Week 0 and Week 12 | QLQ-BR 23                    | Y - 12 week mixed exercise | Exercise intervention improved MT and EL. Upper limb MT correlated with improved QoL ($r = 0.61$) | Positive study              |
| Ferrie56            | Y - D0, 3, 7        | LOS, mortality, fatigue scores on univariate analysis only | Y - nutrition supplement | Extra nutritional supplement improves MT and fatigue scores                      | Positive study              |
| Fetterplace57       | Y - D0 and D15      | HGS, malnutrition (PG SGA), MRC score | Y - nutrition supplement | Intervention attenuated loss of muscle thickness. No correlation with outcomes measured MT was greater in the group that survived (1.4 cm vs. 0.98 cm) and independent of disease severity (SOFA) | Negative study              |
| Galindo Martin29    | N                   | Mortality, NUTRIC status     | N            | MT was greater in the group that survived (1.4 cm vs. 0.98 cm) and independent of disease severity (SOFA) | Positive study              |
| Gomes50             | N                   | SARC-F - sarcopenia risk     | N            | US measure of MT correlates with SARC-F score                                      | Positive study              |
| Greening49          | N                   | Readmission, death, LOS      | N            | Small RF CSA associated with increased risk of death and readmission and LOS      | Positive study              |
| Gruther30           | Y - 17 patients. Sporadic measures | LOS                       | N            | US measure of MT correlates with LOS on ITU                                      | Positive study              |
| Guerreiro66         | N                   | Functional decline, death, readmission at 3 months | N            | US of MT may predict functional decline, rehospitalization, and death             | Positive signals            |
| Hari31              | N                   | Readmission and death        | N            | A low psoas muscle index on US predicted risk of hospitalization and death        | Positive study              |
| Hayes47             | Y - D0, 10, and 20  | MRC score, HGS, ICU mobility scale | N            | US can detect muscle loss and EI correlated with strength and mobility scores     | Positive study              |
| Lee32               | Y - D1, D7, D14 and at D/C | 60 day mortality, mNUTRIC, SARCF, CFS, ADL | N            | 1% reduction in MT on ITU = 5% increase in 60 day mortality                         | Positive study              |
| Mayer23             | Y - D1 and D7       | ITU-acquired weakness, StS   | N            | EI change during first 7 days correlated with physical function (ITU-AW) at discharge | Positive study              |
| Maynard-Paquette24  | N                   | Acute admissions, disease severity using symptom tool and FEV1 | N            | US quadriceps contractile index correlates with disease symptoms and severity | Positive study              |
| McNelly58           | Y - D1, 7, and 10   | Functional (sit to stand)     | Y - intermittent vs. Cont feed | No impact from intervention. SMUS not associated with functional status | Negative study              |
| First author | Serial measurements | Clinical outcome investigated | Intervention | Main conclusion | Positive or negative study |
|--------------|---------------------|------------------------------|--------------|----------------|--------------------------|
| Mueller      | N                   | Discharge destination, frailty index | N            | Muscle US predicts discharge destination in acute surgical patients | Positive study |
| Nakano       | N                   | Exercise tolerance (CPET variables) | N            | Increased EI of thigh muscle is associated with worse exercise tolerance (based on peak VO2) | Positive study |
| Nijholt      | N                   | HGS, S1S, ISWT               | N            | US correlates modestly with total FFM and HGS | Negative study |
| Palakshappa  | Y - D0 and D7       | MRC score and physical function in ITU (PFIT-s) | N            | Only modest correlation with functional strength at Day 7 | Negative study |
| Parry        | Y - D1, 3, 5, 7, 10, and D/C | ITU-acquired weakness | N            | MT and EI correlated with functional status at discharge | Positive study |
| Pita         | Y - every 2 days    | Survival                     | N            | RF CSA is associated with worse survival | Positive study |
| Puthucheary  | Y - D1 and D7       | Muscle strength (MRC score)   | N            | Changes in RF CSA during critical illness predicted functional weakness | Positive study |
| Rodrigues    | Y - every 2 days    | Nutrition status (GLIM, PGSGA), LOS, LOMV, death | N            | No correlation with outcomes measured | Negative study |
| Sabatino     | Y - D0 and D5       | Discharge destination         | N            | Severe muscle loss on US predicted LOS and discharge destination. OR 0.04 (0.0 – 0.74) | Positive study |
| Salim        | N                   | Post-op complications and frailty | N            | US thigh identifies frail patients. Non-significant trend towards complication rates | Negative study —non-significant trend only |
| Sato         | N                   | Fitness (on CPET) and functional capacity | N            | RF MT correlates well with exercise tolerance and physical fitness | Positive study |
| Sahatheven   | N                   | Nutrition status as per ISRN criteria for PEW | N            | US measures of RF CSA correlate with malnutrition and outperform indirect methods | Positive study |
| Tanaka       | Y - alternate days  | Physical function as per Barthel ADL index, LOCCS | N            | Change in RF thickness is associated with LOS and functional capacity after 30 days | Positive study |
| Toledo       | Y - alternate days  | Survival, need for MV         | N            | Decrease in MT was associated with longer need for mechanical ventilation | Positive study |
| Witteveen    | N                   | ITU-acquired weakness (MRC score < 4) | N            | Ultrasound does not predict ICU-AW | Negative study |
| Ye           | N                   | HRQoL, functional assessment, disease severity (GOLD) | N            | EI on US is associated with QoL, physical functioning, and disease severity | Positive study |

6MWT, 6 min walk test; ADL, activities of daily living; ASPEN, American Society of Parenteral and Enteral Nutrition; BB, biceps brachii; CFS, clinical frailty score; CKD, chronic kidney disease; COPD, chronic obstructive pulmonary disease; CPET, cardiopulmonary exercise testing; CSA, cross-sectional area; D/C, discharge; ECMO, extra-corporeal membrane oxygenation; EI, echointensity; FCR, flexor carpi radialis; FEV1, forced expiratory volume 1; FFM, fat free mass; FL, fascicle length; GOLD, Global Initiative for Chronic Obstructive Lung Disease; GOS-E, Global Outcome Scale - Extended; HGS, hand grip strength; ICU, intensive care unit; ISRN, International Society of Renal Nutrition and Metabolism; ISWT, intermittent shuttle walk test; ITU, intensive therapy unit; ITU-AW, intensive therapy unit-acquired weakness; LBM, lean body mass; LOCCS, length of critical care stay; LOMV, length of mechanical ventilation; LOS, length of stay; MRC, medical research council strength score; MT, muscle thickness; MVCQ, mean voluntary contraction index; NUTRIC, nutritional risk in critically ill; PA, pennation angle; PEW, protein energy wasting; PGS-GA, Patient-Generated Subjective Global Assessment; PMI, psoas muscle index; PHR, psoas to height ration; QLQ-BR, Quality of Life Questionnaire - Breast Cancer; QoL, quality of life; RF, rectus femoris; SA, surface area; SARC-F, strength, assistance, rising, climbing, and falls score; SF-36, short form-36; SOFA, Sequential Organ Failure Assessment; SOP, standard operating procedure; STS, sit to stand; TA, tibialis anterior; US, ultrasound; VI, vastus intermedius.
the variety and frequency of different outcomes investigated. Outcomes investigated were categorized into survival, length of stay, hospital (re)admission, functional capacity (including intensive care unit-acquired weakness), physical fitness, nutritional risk status, quality of life, discharge destination, and need for mechanical ventilation.

Cross-sectional area of rectus femoris (RF) and muscle thickness of the quadriceps [combining RF and vastus intermedius (VI) thickness] were the most frequently measured metrics used to correlate against a clinical or functional outcome measure. Of the 10 studies that investigated echointensity of quadriceps (indicating muscle quality/fat content), 7 found statistically significant correlations with clinical and functional outcomes. Twenty studies took serial measurements of the same muscle group to describe longitudinal changes in muscle mass. All 20 of these longitudinal studies found statistically significant changes in muscle measurements over time, which ranged from 15% to 30% reduction in muscle measurement between Day 0 (baseline) and Day 20.

Ultrasound technique and protocol

Adequate detail regarding the equipment used and scan technique was reported in 86% of the studies. These studies described a clear and reproducible protocol regarding anatomical landmarks, ultrasound settings, and image analysis methods. The remaining 14% lacked enough detail to allow reproducibility of scan technique. Despite this, these studies remained in the review analysis due to their relevance and otherwise good methodological quality (checklist score > 6). Bright mode (B-mode) ultrasound with frequencies between 3 and 15 MHz was used by all the reporting studies. Linear transducers were used in most of the studies (94%), and curved array transducers used in remaining 6%. Only half of the studies (54%) reported inter-rater and intra-rater reliability to determine agreement between scans. In these studies, intraclass correlation coefficients ranged from 0.82 to 0.99 indicating good reliability and reproducibility of the technique used.

Quadriceps femoris (RF, VI, lateralis, or medialis) was the most frequently scanned muscle group and investigated in all but one of the included studies. Other groups included biceps brachii, tibialis anterior, flexor carpi radialis, and psoas. Four of the studies included both upper and lower limb measurements. The most frequently adopted anatomical landmarks were the midpoint of the thigh between anterior superior iliac spine and the superior border of patella (38%), the distal point measured at 2/3rd distance (24%), or both (16%). Other novel measurement landmarks were the distal 75% and 60% point of the thigh (n = 4), justified by the point at which the whole of RF could be included in the image. Only four of the studies used maximum probe compression technique with minimum probe compression being used in the majority.

Ultrasound metrics measured included muscle thickness, CSA, echointensity, fascicle length, and pennation angle. Half of the studies measured a single metric only. Muscle thickness and/or CSA was the most frequently used metric measured in 29 of the 37 studies. CSA was measured on its own in seven studies. Echointensity was assessed in only 10 of the studies with fascicle length and pennation angle being rarely measured, appearing in only 2 of the studies. Three of the studies adjusted ultrasound measurements to either the patients’ height, limb length, or body surface area to produce a novel indexed value.

The highest-ranking studies based on the highest methodological quality on the COSMIN and modified 10-point checklist are summarized in Table 2.

Discussion

The main findings from this review indicate that SMUS can be used successfully to detect changes in both muscle mass and quality across a range on clinical contexts. Most studies (76%) described a statistically significant association between ultrasound measurements and a clinical, functional, or nutritional outcome measure. It is worth noting that 26/37 of the studies included in this review had <80 patients in their primary analysis. Several of the studies were underpowered and are at risk of type 1 error, which might overestimate the ability of ultrasound to predict outcomes.

The validity and reliability of SMUS has been subject of recent systematic review and shown to correlate well with other reference measures of muscle mass, even in clinical populations. It is noteworthy that just over half of the studies in this review reported inter-rater and intra-rater reliability to determine agreement between scans. In other words, nearly half of the studies did not report an attempt to internally validate their scan measurements, which may undermine their results. There were common themes reported in terms of ultrasound technique with most studies using either the midpoint of the thigh or the 2/3rd landmark. Despite this, significant heterogeneity still existed with 9 different ultrasound techniques described across the 37 studies. This variation in technique, again, may weaken the conclusions made from this review. Recent work by the Sarcopenia Ultrasound Group (SARCUS) has attempted to offer a standardized technique to measure muscle parameters by consolidating all the known literature and offering consensus expert guidelines. The importance of developing a validated and standardized approach therefore remains imperative to the strength of future research.
Table 2: Summary and key findings of the five studies with the highest methodology quality score

| First author | Quality indicator score | Clinical context | n = | Study design | Muscle group | US metric | Serial measure | Outcome investigated | Main findings | Conclusion |
|--------------|-------------------------|------------------|-----|--------------|--------------|-----------|-----------------|----------------------|--------------|------------|
| Akazawa      | 23                      | Subacute - geriatric rehab | 404 | P-Ob        | RF, VI       | MT, EI    | N               | Functional capacity measured by Barthel Index of ADL | EI correlates with BI score at discharge ($\beta = -0.13, P < 0.01$) and BI score change during admission ($\beta = -0.23, P < 0.01$). No correlation was seen with muscle thickness. | Intramuscular fat infiltration, detected by ultrasound echointensity, correlates with worse recovery of ADLs in older patients |
| Greening     | 59                      | Acute - COPD     | 191 | Subgroup analysis of RCT | RF | CSA   | N               | Survival, readmission, LOS | Patients with smaller RF CSA were more likely to be readmitted or die within 12 months (odds ratio 0.46, 95% CI 0.22–0.95; $P = 0.035$) and had longer LOS (28.1 vs. 12.2 days, $P = 0.007$). | Ultrasound measure of RF CSA predicted readmission, survival, and LOS |
| Mueller      | 48                      | ITU - surgical   | 102 | P-ObCo      | RF | CSA (sex adjusted) | N               | Discharge destination, LOS | Low muscle mass on US independently associated with adverse discharge destination (OR 7.49, CI 1.4–38.2) and overall LOS. | Ultrasound measure of sex-adjusted RF CSA predicted adverse discharge disposition following acute surgical admission |
| Sato         | 53                      | Chronic - HF     | 185 | CS          | RF | MT     | N               | Physical fitness (CPET), nutrition risk (geriatric nutrition risk index) | MT correlated with VO2peak ($\beta = 0.326, P = 0.002$), disease severity (NYHA class), and nutritional risk score ($r = 0.539, P < 0.001$). Low baseline MT (~2.52 cm) was associated with longer ICU stay and longer need for mechanical ventilation. | Ultrasound measure of muscle thickness correlated with exercise tolerance and other health-related outcomes in patients with heart failure. Baseline low muscle mass on ultrasound can predict adverse ICU outcomes |
| Dimopoulos   | 28                      | ITU - cardiac surgery | 165 | P-Ob        | RF, VI | MT | Y - D1, 3, 5, 7 | Length of ICU stay and mechanical ventilation | | |

ADL, activities of daily living; CI, confidence interval; COPD, chronic obstructive pulmonary disease; CPET, cardiopulmonary exercise testing; CSA, cross-sectional area; EI, echointensity; HF, heart failure; ICU, intensive care unit; ITU, intensive treatment unit; LOS, length of stay; MT, muscle thickness; NYHA, New York Heart Association; OR, odds ratio; RCT, randomized control trial; RF, rectus femoris; US, ultrasound; VI, vastus intermedius.
Although more convenient and practical than CT, MRI, or DEXA, ultrasound still has limitations in certain clinical populations. Most of the studies in this review excluded some patients from their analysis due to poor image quality. Non-diagnostic images are often encountered in patients with significant peripheral oedema, such as those on intensive care or with renal failure. Patients with significant obesity are also challenging to capture quality images for accurate assessment. This suggests that whilst SMUS is widely applicable, it is not universally achievable across all patients. Indeed, data from the studies that reported on image quality showed that approximately 8% of eligible patients were excluded due to unmeasurable ultrasound images. Advanced techniques such as panoramic image capture or low-frequency curved array transducers may overcome these issues, but these techniques are less well validated and require more specialist training.

It is well established that increasing frailty, multiple comorbidities, and advancing age are all associated with declines in muscle mass and function. Whilst many studies attempted to independently correct for this in their statistical analysis, it remains possible that low muscle mass on ultrasound (or muscle loss during a disease course) is simply a surrogate marker for these confounders, which have an established association with worse clinical outcomes.

The quadriceps was the most commonly studied muscle group due to its accessibility and size. However, there are only limited data on predictive equations to estimate whole body muscle mass based on limb measurements alone. It is therefore conceivable that appendicular measures of muscle (or changes over time) do not necessarily reflect whole body muscle mass. Further longitudinal investigation of appendicular muscle atrophy measured by ultrasound and its relationship to whole body muscle atrophy is therefore required.

Most studies were conducted during acute illness with the majority being based on the intensive care unit. Significant muscle atrophy over short periods have repeatedly been shown in this clinical context due to immobilization, nutritional deficits, and the catabolic effects of critical illness. This review highlights the paucity of data available from more chronic conditions and the very limited data from other vulnerable groups such as those with cancer. Baseline sarcopenia, or acute muscle wasting during cancer treatment, is associated with increased treatment complications, reduced quality of life, and reduced survival. Further research in high-risk patients with cancer is recommended to investigate if SMUS can complement, or even outperform, current nutritional assessment and help identify patients that need more intensive support through treatment.

The radiological assessment of muscle quality is gaining increasing attention as a potentially more important radiological metric than simple mass measurement. Early evidence suggests that muscle quality may deteriorate before muscle mass and is independently associated with physical fitness, function, and survival. Myosteatosis (fat infiltration of muscle) is measured by radiodensity on CT scan and echogenicity (also known as echointensity) using grayscale analysis on ultrasound. Only, 10 of the studies in this review measured echointensity, with 7 of them finding significant associations with outcome measures, namely, physiological status (VO2max), quality of life, and functional status at discharge. However, measurement of echointensity is more technically demanding and depends on ultrasound frequency, gain, tissue depth, and the analysis technique used. Several studies have offered a standardized technique to improve reproducibility, but further research is required to correlate ultrasound echogenicity with current reference techniques such as CT radiodensity.

Finally, most of the studies in this review found a significant correlation between ultrasound metrics and outcome measures with only nine negative studies. Publication bias, with the underreporting of negative studies, remains a significant possibility that requires acknowledgement. It is therefore important that negative ultrasound research is also published alongside positive studies to improve our understanding of the technique and its generalizability in clinical practice.

Conclusions

This review has shown that SMUS has been used to assess muscle quality and quantity across a broad range of clinical settings and can detect alterations in muscle during a disease course. Ultrasound metrics such as muscle thickness, CSA, and echointensity have been used to predict clinical and functional outcomes in both acute and chronic clinical conditions. Muscle ultrasound continues to gain momentum as a bedside tool to quantify and monitor skeletal muscle. However, firm conclusions from this review are hindered by the heterogeneity and lack of standardized technique. Continued research is therefore required to further validate and standardize the technique, but also to establish cut-off values in different clinical populations. Further longitudinal research is also required in other cohorts, especially in clinical conditions where the prevalence of malnutrition and sarcopenia are high, such as patients with cancer.

Acknowledgements

The authors certify that this article clinically complies with the ethical guidelines for authorship and publishing in the Journal of Cachexia, Sarcopenia and Muscle.
Conflict of interest

The authors report no conflict of interest. There was no funding associated with the production of this article.

References

1. Muscaritoli M, Arends J, Bachmann P, Baracos V, Barthelemy N, Bertz H, et al. ESPEN practical guideline: Clinical Nutrition in cancer. Clin Nutr 2021;40:2898–2913.

2. Jensen GL, Cederholm T, Correia MITD, Gonzalez MC, Fukushima R, Higashiguchi T, et al. GUM criteria for the diagnosis of malnutrition: a consensus report from the global clinical nutrition community. J Parenter Enter Nutr 2019;43:32–40.

3. Simonsen C, de Heer P, Bjerré ED, Suetta C, Hojman P, Pedersen BK, et al. Sarcopenia and postoperative complication risk in gastrointestinal surgical oncology: a meta-analysis. Ann Surg 2018;268. https://journals.lww.com/annalsurgery/Fulltext/2018/07000/Sarcopenia_and_Postoperative_Complexion_Risk_in_12.aspx

4. Zhang XM, Chen D, Xie XH, Zhang JE, Zeng Y, Cheng ASK. Sarcopenia as a predictor of mortality among the critically ill in an intensive care unit: a systematic review and meta-analysis. BMC Geriatr 2021;21:399.

5. Lee CM, Kang J. Prognostic impact of myosteatosis in patients with colorectal cancer: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2020;11:1270–1282.

6. Sepúlveda-Loyola W, Osadnik C, Phu S, Morita AA, Duque G, Probst VS. Diagnosis, prevalence, and clinical impact of sarcopenia in COPD: a systematic review and meta-analysis. J Cachexia Sarcopenia Muscle 2020;11:1164–1176.

7. Zhao Y, Zhang Y, Hao Q, Ge M, Dong B. Sarcopenia and hospital-related outcomes in the old people: a systematic review and meta-analysis. Aging Clin Exp Res 2019;31:5–14.

8. Pamoukdjian F, Bouillet T, Lévy V, Soussan M, Zelek L, Paillaud E. Prevalence and prevalence of sarcopenia in older individuals: a clinical perspective. J Am Med Dir Assoc 2018;19:280–300.

9. Peronti F, Umbrello M, Coppola S, Froio S, Chiumello D. Clinical review: peripheral muscular ultrasound in the ICU. Ann Intensive Care 2019;9:57.

10. Perkissas S, Bastjinsk S, Baudry S. For the full SARCUS working group, Sanchez-Rodriguez D, Piotrowicz K, et al. Application of ultrasound for muscle assessment in sarcopenia: 2020 SARCUS update. Eur Geriatri Med Published online 2021;12:427–428.

11. Pretorius A, Keating JL. Validity of real time ultrasound for measuring skeletal muscle size. Phys Ther Rev 2008;13:415–426.

12. Mokkink LB, Boers M, van der Vleuten CPM, van der Vleuten CPM, Bouter LM, Alonso J, et al. COSMIN Risk of Bias tool to assess the quality of studies on reliability or measurement error of outcome measurement instruments: a Delphi study. BMC Med Res Methodol 2020;20:293.

13. McHugh ML. Interrater reliability: the kappa statistic. Biochem Med 2012;22:276–282.

14. Prado CMM, Lieffens JR, McCargar LJ, Prado CMM, Lieffens JR, McCargar LJ, et al. GLIM criteria for the diagnosis of malnutrition: a consensus report from the global clinical nutrition community. J Parenter Enter Nutr 2019;43:32–40.

15. Paris MT, Lafluer B, Dubin JA, Mourtzakis E, Kummerlen C, Leung R, Stollery D, et al. Bedside ultrasound is a practical and reliable measurement tool for assessing quadriceps muscle layer thickness. J Parenter Enter Nutr 2014;38:886–890.

16. Tinciné A, Meschi T, Narici MV, Lauretani F, Maggio M. Muscle ultrasound and sarcopenia in older individuals: a clinical perspective. J Am Med Dir Assoc 2018;19:280–300.

17. Tinciné A, Meschi T, Narici MV, Lauretani F, Maggio M. Muscle ultrasound and sarcopenia in older individuals: a clinical perspective. J Am Med Dir Assoc 2018;19:280–300.

18. Formenti P, Umbrello M, Coppola S, Froio S, Chiumello D. Clinical review: peripheral muscular ultrasound in the ICU. Ann Intensive Care 2019;9:57.

19. Perkissas S, Bastjinsk S, Baudry S. For the full SARCUS working group, Sanchez-Rodriguez D, Piotrowicz K, et al. Application of ultrasound for muscle assessment in sarcopenia: 2020 SARCUS update. Eur Geriatri Med Published online 2021;12:427–428.

20. Pretorius A, Keating JL. Validity of real time ultrasound for measuring skeletal muscle size. Phys Ther Rev 2008;13:415–426.

21. Mokkink LB, Boers M, van der Vleuten CPM, van der Vleuten CPM, Bouter LM, Alonso J, et al. COSMIN Risk of Bias tool to assess the quality of studies on reliability or measurement error of outcome measurement instruments: a Delphi study. BMC Med Res Methodol 2020;20:293.

22. McHugh ML. Interrater reliability: the kappa statistic. Biochem Med 2012;22:276–282.
between ultrasound quadriiceps muscle status with premorbid functional status and 60-day mortality in mechanically ventilated critically ill patient: a single-center prospective observational study. *Clin Nutr (Edinburgh, Scotland)* 2021;40:1338–1347.

33. Mayer KP, Thompson Bastin ML, Montgomery-Yates AA, Pastva AM, Dupont-Versteegden EE, Parry SM, et al. Acute skeletal muscle wasting and dysfunction predict physical disability at hospital discharge in patients with critical illness. *Crit Care (London, England)* 2020;24:637.

34. Maynard-Paquette AC, Poirier C, Chartrand-Lefebvre C, Dubé BP. Ultrasound evaluation of the quadriceps muscle contractile index in patients with stable chronic obstructive pulmonary disease: relationships with clinical symptoms, disease severity and diaphragm contractility. *Int J Chron Obstruct Pulmon Dis* 2020;15:75–88.

35. Palakshappa JA, Reilly JP, Schweickert WD, Anderson BJ, Khoury V, Shashaty MG, et al. Quantitative peripheral muscle ultrasound in sepsis: muscle area superior to thickness. *J Crit Care* 2018;47:324–330.

36. Parry SM, El-Ansary D, Cartwright MS, Sarwal A, Bensley S, Koopman R, et al. Ultrasoundography in the intensive care setting can be used to detect changes in the quality and quantity of muscle and is related to muscle strength and function. *J Crit Care* 2015;30:1151.e9–1151.e14.

37. Puthucheary ZA, McNelly AS, Rawal J, Connolly B, Sidhu PS, Rowlerson A, et al. Rectus femoris cross-sectional area and muscle layer thickness: comparative markers of muscle wasting and weakness. *Am J Respir Crit Care Med* 2016;195:136–138.

38. Rodrigues CN, Ribeiro Henrique J, Ferreira AR, Correia MITD. Ultrasoundography and other nutrition assessment methods to monitor the nutrition status of critically ill patients. *JPN J Parenter Enteral Nutr* 2021;45:982–980.

39. Sabatino A, Maggiore U, Regolisti G, Rossi GM, di Mario F, Gentile M, et al. Ultrasound for non-invasive assessment and monitoring of quadriiceps muscle thickness in critically ill patients with acute kidney injury. *Front Nutr* 2021;8:622823.

40. Salim SY, Al-Khathiri O, Tandon P, Baracos VE, Churchill TA, Warkentin LM, et al. Thigh ultrasound used to identify frail elderly patients with sarcopenia undergoing surgery: a pilot study. *J Surg Res* 2020;256:422–432.

41. Tanaka Y, Yamada T. Ultrasound measurement of septic shock-induced acute skeletal muscle atrophy in intensive care unit. *PM&R* 2021;13:347–352.

42. Toledo DC, de Freitas BJ, Dil R, do Amaral Pfeilsticker FJ, Dos Santos DM, Gomes BC, et al. Peripheral muscular ultrasound as an outcome measurement tool in critically ill patients on mechanical ventilation: an observational cohort study. *Clin Nutr ESPEN* 2021;43:408–414.

43. Witteveen E, Sommers J, Wieske L, Doorduin J, van Alfen N, Schultz MJ, et al. Diagnostic accuracy of quantitative neuromuscular ultrasound for the diagnosis of intensive care unit-acquired weakness: a cross-sectional observational study. *Ann Intensive Care* 2017;7:40.

44. Bury C, DeChicco R, Nowak D, Lopez R, He L, Jacob S, et al. Use of bedside ultrasound to assess muscle changes in the critically ill surgical patient. *J Parenter Enteral Nutr* 2021;45:394–402.

45. Escriche-Escudar A, Trinidad-Fernández M, Pajares B, Iglesias-Campos M, Alba E, Cuesta-Vargas AI, et al. Ultrasound use in metastatic breast cancer to measure body composition changes following an exercise intervention. *Sci Rep* 2021;11:8858.

46. Guerrero AC, Tonelli AC, Orzechowski R, Dalla Corte RR, Moriguchi EH, de Mello RB. Bedside ultrasound of quadriiceps to predict rehospitalization and functional decline in hospitalized elders. *Front Med* 2017;4:122.

47. Hayes K, Holland AE, Pellegrino VA, Mathur P, Chomaitien S, Pfeilsticker FJ, Dos Santos DM, Gomes BC, et al. Use of bedside ultrasound and ultrasound-measured thigh muscle area to assess muscle loss during critical illness and survivors of septic shock: observational prospective cohort study. *J Crit Care* 2018;41:8–18.

48. Mueller N, Murthy S, Tainter CR, Lee J, Riddell K, Fintelmann FJ, et al. Can sarcopenia quantified by ultrasound of the rectus femoris muscle predict adverse outcome of surgical intensive care unit patients as well as frailty? A prospective, observational cohort study. *Ann Surg 2016;264*:1116–1124.

49. Pita A, Ziegas IA, Ye F, Chen Y, Rauf MA, Nakamura T, Yamano T, et al. Clinical significance of sarcopenia muscle wasting in esophageal cancer: a retrospective cohort study. *J Surgery* 2020;44:1103–1109.

50. Nakano I, Hori H, Fukushima A, Tsuchiya S, Hodgson CL. Acute skeletal muscle wasting and relation to physical function in patients requiring extracorporeal membrane oxygenation (ECMO). *J Crit Care* 2018;48:1–8.

51. Nakano I, Hori H, Fukushima A, Yokota T, Nishimura A, Fujita M, et al. Quantitative muscle mass using ultrasound predicts rehospitalization in patients awaiting liver transplantation in the intensive care unit. *Transplant Direct* 2020;6:e618.

52. Gomes TTN, Borges TC, Pichard C, Pimentel GD. Correlation between SARC-F score and ultrasound-measured thigh muscle thickness in older hospitalized cancer patients. *J Nutr Health Aging* 2020;24:1128–1130.

53. Nakano I, Hori H, Fukushima A, Yokota T, Kinugawa S, Tsuchiya S, et al. Enhanced echo intensity of skeletal muscle is associated with exercise intolerance in patients with heart failure. *J Card Fail* 2020;26:685–693.

54. Nijholt W, Ter Beek L, Hobbelen N, van der Vaart H, Weempe JB, van der Schans CP, et al. The added value of ultrasound muscle measurements in patients with COPD: an exploratory study. *Clinical Nutrition ESPEN* 2019;30:152–158.

55. Sato Y, Shiraiishi H, Nakanishi N, Zen K, Nakamura T, Yamano T, et al. Clinical significance of rectus femoris diameter in heart failure patients. *Heart Vessels* 2020;35:672–680.

56. Sahathevan S, Khor BH, Singh BKS, Sabatino A, Fiaccadori E, Daud Z, et al. Association of ultrasound-derived metrics of the quadriceps muscle with protein energy wasting in hemodialysis patients: a multicenter cross-sectional study. *Nutrients* 2020;12:3597.

57. Ye X, Wang M, Xiao H. Echo intensity of the rectus femoris in stable COPD patients. *Int J Chron Obstruct Pulmon Dis* 2017;12:3007–3015.

58. Ferrie S, Allman-Farinelli M, Daley M, Smith K. Protein requirements in the critically ill. *J Parenter Enteral Nutr* 2016;40:795–805.

59. Pfeilsticker FJ, Dos Santos DM, Gomes BC, et al. Assessment of body composition and sarcopenia in patients with esophageal cancer: a systematic review and meta-analysis. *Dis Esophagus* 2018;31:doy047.

60. Järvinen T, Ilonen I, Kauppi J, Salo J, Räsänen J. Loss of skeletal muscle mass during neoadjuvant treatments correlates with worse prognosis in esophageal cancer: a retrospective cohort study. *World J Surg Oncol* 2018;16:27.

61. West MA, van Dijk D, Gelewee F, Reeves T, Primrose JN, Abu Hilal M, et al. Myosteatosis is associated with poor physical fitness in patients undergoing hepatopancreaticobiliary surgery. *J Cachexia Sarcopenia Muscle* 2019;10:860–871.

62. Ahn H, Kim DW, Ko Y, Ha J, Shin YB, Lee J, et al. Updated systematic review and meta-analysis on diagnostic issues and the prognostic impact of myosteatosis: a new paradigm beyond sarcopenia. *Aging Res Rev* 2021;70:101398.

63. Rollins KE, Tewari N, Ackner A, Awward A, Madhusudan S, Macdonald IA, et al. The impact of sarcopenia and myosteatosis on outcomes of unresectable pancreatic cancer or distal cholangiocarcinoma. *Clin Nutr* 2016;35:1103–1109.

64. von Haehling S, Morley JE, Coats AIS, Anker SD. Ethical guidelines for publishing in the Journal of Cachexia, Sarcopenia and Muscle: update 2021. *J Cachexia Sarcopenia Muscle* 2021;12:2259–2261.